Physician profile
Jonathan Barrus
NPI 1346654589
$2,694.01
in general payments reported to CMS, 2019-2025
40 companies · $720 in 2025
The $720 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $156 · 2021: $331 · 2022: $456 · 2023: $557 · 2024: $475 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,751.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $597.73 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $266.71 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $200.76 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $193.33 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals Lp | $125.57 | 2020-2025 | Farxiga, Airsupra |
| Pfizer INC. | $108.43 | 2021-2024 | |
| Mylan Specialty L.P. | $81.93 | 2022-2024 | Yupelri |
| Glaxosmithkline, LLC. | $81.10 | 2023-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.36 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $70.03 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $67.66 | 2023-2024 | |
| Astellas Pharma US INC | $64.46 | 2020-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $56.20 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $47.89 | 2023-2025 | |
| Corcept Therapeutics | $47.63 | 2025 | Korlym |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Barrus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.